Analysts Set Insulet Co. (NASDAQ:PODD) Price Target at $292.06

Insulet Co. (NASDAQ:PODD - Get Free Report) has been given an average recommendation of "Moderate Buy" by the seventeen research firms that are covering the company, MarketBeat.com reports. Three research analysts have rated the stock with a hold rating and fourteen have issued a buy rating on the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $292.06.

A number of equities research analysts have commented on the company. Citigroup raised their price objective on Insulet from $310.00 to $355.00 and gave the company a "buy" rating in a research note on Friday, February 21st. StockNews.com downgraded shares of Insulet from a "buy" rating to a "hold" rating in a research report on Tuesday, March 4th. TD Cowen upped their price objective on shares of Insulet from $264.00 to $324.00 and gave the stock a "buy" rating in a report on Friday, January 3rd. Piper Sandler lifted their price objective on shares of Insulet from $285.00 to $310.00 and gave the company an "overweight" rating in a report on Friday, February 21st. Finally, Royal Bank of Canada began coverage on shares of Insulet in a research report on Thursday, March 6th. They set an "outperform" rating and a $340.00 target price for the company.

Remove Ads

Insider Buying and Selling at Insulet

In related news, Director Wayne A.I. Frederick sold 1,825 shares of the stock in a transaction on Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total value of $501,875.00. Following the sale, the director now owns 3,231 shares in the company, valued at approximately $888,525. This trade represents a 36.10 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Eric Benjamin sold 12,394 shares of Insulet stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total value of $3,470,320.00. Following the sale, the executive vice president now directly owns 11,383 shares of the company's stock, valued at $3,187,240. This represents a 52.13 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.47% of the company's stock.

Institutional Trading of Insulet

Several institutional investors and hedge funds have recently modified their holdings of PODD. Baillie Gifford & Co. increased its position in shares of Insulet by 3.5% in the fourth quarter. Baillie Gifford & Co. now owns 2,355,683 shares of the medical instruments supplier's stock worth $614,998,000 after purchasing an additional 79,982 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Insulet by 2.3% during the 4th quarter. Geode Capital Management LLC now owns 1,779,167 shares of the medical instruments supplier's stock worth $463,347,000 after acquiring an additional 40,566 shares during the last quarter. Norges Bank purchased a new position in Insulet in the fourth quarter worth $248,806,000. Artisan Partners Limited Partnership increased its stake in Insulet by 24.1% in the fourth quarter. Artisan Partners Limited Partnership now owns 770,188 shares of the medical instruments supplier's stock valued at $201,073,000 after acquiring an additional 149,524 shares during the last quarter. Finally, Northern Trust Corp raised its position in Insulet by 20.5% during the fourth quarter. Northern Trust Corp now owns 738,811 shares of the medical instruments supplier's stock valued at $192,881,000 after purchasing an additional 125,710 shares in the last quarter.

Insulet Trading Up 0.8 %

Shares of Insulet stock traded up $2.20 on Friday, reaching $265.38. 221,212 shares of the company's stock were exchanged, compared to its average volume of 704,497. The company has a market capitalization of $18.64 billion, a P/E ratio of 45.86, a price-to-earnings-growth ratio of 3.62 and a beta of 1.29. Insulet has a 52 week low of $160.19 and a 52 week high of $289.46. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. The firm's 50-day moving average is $271.17 and its two-hundred day moving average is $259.40.

Insulet (NASDAQ:PODD - Get Free Report) last released its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.00 by $0.15. The company had revenue of $597.50 million for the quarter, compared to analysts' expectations of $582.02 million. Insulet had a net margin of 20.19% and a return on equity of 24.46%. Sell-side analysts predict that Insulet will post 3.92 EPS for the current fiscal year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.